Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) & BELEODAQ® (belinostat) for injection a...
March 31 2017 - 7:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development
operations with a primary focus in Hematology and Oncology, today
announced key presentations of clinical and scientific data related
to its products at the American Association for Cancer Research
(AACR) Annual Meeting being held in Washington, D.C.,
from April 1-5, 2017.
The following ROLONTIS™ (eflapegrastim) related abstract
is being presented at the AACR meeting:
Monday, April 3, 2017:
Abstract # Type
Title First Author
Time 1347 Poster In vivo efficacy of eflapegrastim in rats
with chemotherapy-induced neutropenia Kim 8:00 AM -12:00 PM
The following key BELEODAQ® (belinostat) for
injection related abstracts are being presented at the AACR
meeting:
Monday, April 3, 2017:
Abstract # Type
Title First Author
Time 1059 Poster Enhanced anti-tumor efficacy of a
checkpoint inhibitor in combination with the HDAC inhibitor
belinostat in a murine hepato-cellular carcinoma preclinical model
Llopiz 8:00 AM-12:00 PM 2018 Poster Synergistic interactions
between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells
occur in vitro and in vivo and proceed through multiple mechanisms
Nguyen 1:00 PM-5:00 PM
For more information about the AACR meeting and for a complete
list of abstracts, please refer to the conference website
at http://www.abstractsonline.com/pp8/#!/4292.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in Hematology and Oncology. Spectrum
currently markets six hematology/oncology drugs, and has an
advanced stage pipeline that has the potential to transform
the Company. Spectrum's strong track record for in-licensing and
acquiring differentiated drugs, and expertise in clinical
development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase
3 studies. More information on Spectrum is available
at www.sppirx.com.
Forward-looking statement - This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and
Exchange Commission. The Company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC. and BELEODAQ® are registered
trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates.
REDEFINING CANCER CARE™, and ROLONTIS™ and the Spectrum
Pharmaceuticals' logos are trademarks owned by Spectrum
Pharmaceuticals, Inc. Any other trademarks are the property of
their respective owners.
© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170331005077/en/
Spectrum Pharmaceuticals, Inc.Shiv Kapoor, 702-835-6300Vice
President, Strategic Planning & Investor
RelationsInvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Sep 2023 to Sep 2024